HUWE1 Reaches Mitochondria via RMC1 to Drive Brain Development
Scientists crack how a key intellectual disability gene targets mitochondria, revealing a new therapeutic angle for neurodevelopmental disorders.
Summary
Mutations in HUWE1, a major cause of X-linked intellectual disability (XLID), have long puzzled researchers because many variants don't impair the enzyme's catalytic activity. This study reveals that HUWE1 relies on an adaptor protein called RMC1—itself recruited to mitochondria by AMBRA1—to reach and ubiquitinate mitochondrial targets. Disease-associated noncatalytic variants (M375I, G660R, H669Q) disrupt this localization step, not catalytic function per se. In zebrafish models, these variants reproduced hallmark neurodevelopmental deficits including impaired brain growth and motor neuron dysfunction. Global ubiquitin profiling confirmed that mitochondrial, but not nuclear, substrates were selectively disrupted. Importantly, treatment with Urolithin A—a natural compound that boosts mitophagy—partially rescued these phenotypes, pointing toward mitochondrial quality control as a tractable therapeutic strategy.
Detailed Summary
X-linked intellectual disability (XLID) affects roughly 1–3 per 1,000 males and HUWE1 mutations represent one of its most recurrent genetic causes. HUWE1 encodes a large HECT-domain E3 ubiquitin ligase involved in protein homeostasis, DNA damage response, and neural progenitor regulation. A longstanding mystery has been that a significant fraction of XLID-associated HUWE1 variants are noncatalytic—they do not impair ubiquitin-ligase activity itself—leaving their pathogenic mechanism unknown.
This study uncovers an AMBRA1–RMC1–HUWE1 signaling axis that directs HUWE1 specifically to mitochondria. AMBRA1, previously known primarily as an autophagy scaffold, acts here as a mitochondrial docking platform that recruits RMC1. RMC1 in turn binds HUWE1 directly, ferrying it to the mitochondrial surface where it ubiquitinates mitochondrial substrate proteins to facilitate their turnover. This spatial targeting mechanism is entirely separate from catalytic activity, explaining why noncatalytic variants can still cause disease.
Using zebrafish as an in vivo model, the authors introduced three XLID patient variants—M375I, G660R, and H669Q—and observed robust neurodevelopmental phenotypes: reduced brain size, aberrant motor neuron architecture, and locomotor deficits mirroring clinical presentations. To dissect substrate specificity, they performed global ubiquitin proteomics comparing wild-type and variant fish. Strikingly, only mitochondrial protein ubiquitination was reduced; nuclear substrates were unaffected, confirming that the AMBRA1–RMC1 axis selectively routes HUWE1 to mitochondria and that noncatalytic variants specifically disrupt this routing.
The therapeutic implication is significant: if impaired mitochondrial quality control underlies noncatalytic HUWE1-XLID, then pharmacologically boosting mitophagy could compensate. Urolithin A, a gut-microbiome-derived metabolite and known mitophagy inducer currently in clinical trials for aging-related conditions, was tested in HUWE1-deficient zebrafish and achieved partial rescue of brain and motor neuron phenotypes. While not a cure, this proof-of-concept demonstrates that the downstream mitochondrial dysfunction is pharmacologically addressable.
Caveats include the reliance on zebrafish as the primary in vivo model, which may not fully recapitulate human cortical neurodevelopment. The precise mitochondrial substrates ubiquitinated by HUWE1 via RMC1 remain to be fully catalogued, and the molecular interface between noncatalytic HUWE1 variants and RMC1 binding needs structural resolution. Nonetheless, this work reframes HUWE1-XLID as a disorder of mitochondrial quality control and opens a new mechanistic and therapeutic paradigm.
Key Findings
- HUWE1 is recruited to mitochondria via RMC1, which is anchored there by the scaffold protein AMBRA1.
- Three noncatalytic XLID patient variants (M375I, G660R, H669Q) disrupt mitochondrial targeting, not catalytic activity.
- Global ubiquitin profiling shows selective loss of mitochondrial—but not nuclear—substrate ubiquitination in these variants.
- Zebrafish expressing these variants display reduced brain growth and motor neuron defects resembling human XLID.
- Urolithin A treatment partially rescues neurodevelopmental phenotypes, validating mitochondrial quality control as a therapeutic target.
Methodology
The study used CRISPR/patient-variant knockin zebrafish to model XLID in vivo, with brain morphology and motor neuron imaging as primary readouts. Global ubiquitin proteomics was performed to map substrate compartment specificity. Biochemical interaction studies (co-IP, localization assays) defined the AMBRA1–RMC1–HUWE1 axis mechanistically.
Study Limitations
Zebrafish lack a human-equivalent neocortex, so translational fidelity for cortical phenotypes is uncertain. The full catalog of mitochondrial substrates ubiquitinated through the AMBRA1–RMC1–HUWE1 axis remains incomplete. Urolithin A rescue was partial, and long-term efficacy and safety in a neurodevelopmental context have not been assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: